Transitional Supply of DEC for Lymphatic Filariasis Elimination

Partnership objectives

Supply DEC to low-income countries to aid in global efforts to eliminate Lymphatic Filariasis.

These commitments are a key part of the "Uniting to Combat Neglected Tropical Diseases" partnership. These commitments are a key part of the "Uniting to Combat Neglected Tropical Diseases" partnership. Copyright Uniting to Combat NTDs

What are the health needs and challenges?

Lymphatic Filariasis (or elephantiasis) is a parasitic disease that is transmitted to humans by a mosquito bite. Once transmitted, it causes lymphatic dysfunction that leads to other serious physical disabilities such as elephantiasis. Currently, the disease affects an estimated 120 million people in 73 countries worldwide, mostly in developing and emerging nations in Africa and Southeast Asia.

Lymphatic Filariasis can be treated with a combination of two anti-parasitic agents, including diethycarbamazine (DEC). Large-scale interventions, in which all inhabitants of endemic areas are administered DEC once a year for at least five years, are required to eliminate the disease.

Description of partnership activities and how they address needs and challenges

In 2012 Eisai and Sanofi announced a new partnership with the Bill & Melinda Gates Foundation to join the World Health Organization’s (WHO) Global Program to Eliminate Lymphatic Filariasis by 2020. These commitments are a key part of the "Uniting to Combat Neglected Tropical Diseases" partnership.

Eisai began manufacturing and supplying 2.2 billion tablets of DEC to WHO in October 2013. To ensure a stable of supply of DEC until the Eisai-produced DEC became available, Eisai, Sanofi and the Bill & Melinda Gates Foundation committed to provide 120 million DEC tablets manufactured by Sanofi to the WHO free of charge. This was the first partnership in which two pharmaceutical companies, with the Gates Foundation, came together to supply a single drug for an NTD.

Summary of impact through December 2013 and forward looking information

Sixty million tablets of Diethylcarbamazine 100mg base, were delivered to the WHO in 2012, and 60 million were delivered in 2013. The progress of the Eisai-Sanofi-WHO initiative on Lymphatic Filariasis is monitored through the United to Combat NTDs "London Declaration" Annual Scorecard; latest version released in January 2013.

Partnership information

Company(ies) Eisai , Sanofi

Partner(s) Bill and Melinda Gates Foundation, World Health Organization (WHO)

Type of Partner(s) IGOs, NGOs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Lymphatic Filariasis

Program Type(s) Availability of Treatment - Product Donations, Prevention Programs - Mass Drug Administrations (MDA)

Targeted Population(s) Patients in needs of treatment, People with low income

Region(s) East Asia & Pacific, South Asia, Sub-Saharan Africa

Number of Countries 7

Country(ies) Madagascar, Malaysia, Maldives, Myanmar, Papua New Guinea, Timor-Leste, Zambia

Start Date 2012

More information Press Release

Completed date 2013